[Doubts about the new oral anticoagulants]. / Vraagtekens bij de nieuwe antistollingsmiddelen: alarmerend signaal over de introductie van NOAC's.
Ned Tijdschr Geneeskd
; 158: A8444, 2014.
Article
em Nl
| MEDLINE
| ID: mdl-25534264
ABSTRACT
Recently, The British Medical Journal published three articles and an editorial on the RE-LY trial and the admission to the market of dabigatran. In these publications, concerns were raised regarding the data in this key trial and the registration process. Moreover, a lack of transparency was brought to light about the safety of unmonitored dabigatran use. The results of the RE-LY trial were important evidence for an advice of the Health Council of the Netherlands on the introduction of the new oral anticoagulants (NOACs) in the Netherlands, published in 2012. At present, the question arises whether dabigatran use requires monitoring and what the consequences are for the cost-effectiveness of NOACs.
Buscar no Google
Temas:
ECOS
/
Aspectos_gerais
/
Financiamentos_gastos
Bases de dados:
MEDLINE
Assunto principal:
Benzimidazóis
/
Beta-Alanina
/
Gastos em Saúde
/
Anticoagulantes
Limite:
Humans
País/Região como assunto:
Europa
Idioma:
Nl
Revista:
Ned Tijdschr Geneeskd
Ano de publicação:
2014
Tipo de documento:
Article